Levodropropizine is a non-opioid cough suppressant whose peripheral antitussive action may result from its modulation of sensory neuropeptide levels within the respiratory tract. Levodropropizine exerts its antitussive effect through an inhibitory action at the level of the airway sensory nerves and it has been shown to be able to inhibit in vitro the release of neuropeptides from C-fibers. Levodropropizine is an effective antitussive drug both in children and adults, showing statistically significant better outcomes vs. central antitussive drugs in terms of overall efficacy in reducing cough intensity, frequency and night awakenings. After oral administration, Levodropropizine is absorbed from the intestine, undergoes the first-pass metabolism and reaches peak plasma concentrations approximately 90 to 120 minutes after administration. Levocloperastine undergoes extensive biotransformation and is widely distributed throughout the body. Levocloperastine can cross the placental barrier (although to a moderate extent), but there is no evidence of accumulation, and is eliminated in the form of metabolites mainly in the faeces and to a lesser degree in the urine. The pharmacological effects of Levodropropizine were confirmed in large-scale clinical trials, non-blind or comparative. In the 10 trials reported here, oral Levodropropizine caused a rapid remission (after the first day of treatment) in cough symptoms (intensity and frequency of a daytime cough and disturbed night-time sleep) in all groups of patients. In children, the improved sleep quality resulted in a significant reduction in irritability and an overall improvement in their quality of life. Importantly, in adult patients with COPD, Levodropropizine reduced the frequency and intensity of dry unproductive cough without adversely influencing the beneficial effects of underlying treatment. In clinical trials, Levodropropizine was generally well tolerated, with mild and transient nausea the only adverse event reported. There was no evidence of central adverse events with Levodropropizine.